Shots:

• The VRBPAC voted 20-0- with one abstention that the benefits of the Moderna’s vaccine outweighed its risks for use in people aged ≥18yrs
• The recommendation is based on data analysis from the pivotal P-III clinical study that demonstrated 94.1% efficacy
• The US FDA’s committees provide non-binding recommendations. The FDA will take the VRBPAC’s recommendation into consideration in making a final decision on approval

 ­ Ref: Moderna | Image: Moderna